Salama Abdulgabar
Institute for Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Transfus Med Hemother. 2015 Sep;42(5):311-5. doi: 10.1159/000438960. Epub 2015 Aug 10.
Autoimmune haemolytic anaemias (AIHAs) are well-characterized disorders. They can be differentiated from one another and from other non-immune haemolytic anaemias by clinical, laboratory and serological testing. However, several misleading clinical presentations and/or serological findings may result in misinterpretation, delay and/or misdiagnosis. Such failures are avoidable by adequate clinical and serological experience of the responsible physicians and serologists or, at least, by an optimised bidirectional communication. As long as this has not been achieved, unpleasant failures are to be expected. A true diagnosis of AIHA can neither be verified by clinical nor serological findings alone. Thus, a collective clinical and serological picture remains obligatory for fulfilling the criteria of optimal diagnosis and therapy. Ultimately, the majority of pioneer scientific and practical work in this field stems from scientists who were simultaneously involved in both the clinic and serology.
自身免疫性溶血性贫血(AIHA)是特征明确的疾病。通过临床、实验室和血清学检测,它们可以相互区分,也可以与其他非免疫性溶血性贫血相鉴别。然而,一些具有误导性的临床表现和/或血清学发现可能导致误解、延误和/或误诊。通过负责的医生和血清学家具备足够的临床和血清学经验,或者至少通过优化的双向沟通,此类失误是可以避免的。只要尚未做到这一点,就可能会出现令人不快的失误。AIHA的真正诊断既不能仅通过临床发现,也不能仅通过血清学发现来证实。因此,为了满足最佳诊断和治疗标准,综合的临床和血清学表现仍然是必不可少的。最终,该领域的大多数开创性科学和实践工作都源于同时涉足临床和血清学的科学家。